Petition to Allow Omacetaxine as Treatment for CL

I recently read about a woman's story on Empowerher and I wanted to share how you can help. Nope - no donation required.

Pat tells her story, "there's an important issue impacting my health, and I would appreciate your help. As many of you know, I have a rare form of leukemia, known as chronic myelogenous leukemia, or CML. The National CML Society of the United States, as well as the CML Society of Canada, have identified a serious concern that affects some of my fellow survivors. It involves the Food and Drug Administration review for a drug called Omacetaxine which is a lifeline for those who are dealing with a specific mutation that can affect those with CML."

"In most drug reviews the responsible committee members vote on the clinical efficacy of the drug, but in this case they chose to vote on the lack of a standardized test to determine the presence of the mutation...none of the other tests currently used to diagnose or track our treatments are standardized at this time."

"While the patient support organizations commend the work of the FDA in reviewing Omacetaxine, and indeed all of the drugs currently used to treat this disease, they are dismayed by the sudden change of policy and have developed a petition asking the FDA to re-visit their recommendation and allow Omacetaxine to come to market while the drug manufacturer (ChemGenex) works with labs to standardize mutation testing."

"This is critical to patients who harbor these mutations. We don't know what causes this mutation and can't predict who will develop it, so this could be the fate of any CML patient, including me. Not having a treatment available could be life-threatening.

Please visit the US and Canadian websites and visit the petition page to read more about this important situation and consider providing support by signing the petition.
Thank you!"

United States http://www.nationalcmlsociety.org/
Canada http://www.cmlsociety.org/

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap